Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17156104 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
Condition: Diabetes Mellitus, Type II
Interventions: Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks;   Drug: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Indicates status has not been verified in more than two years